Literature DB >> 21850490

Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum.

Neşe Tunçel1, Orhan Tansel Korkmaz, Neslihan Tekin, Erol Şener, Fahrettin Akyüz, Mine Inal.   

Abstract

6-Hydroxydopamine (6-OHDA) is an oxidative stress neurotoxin, which is oxidized in neurons, causes respiratory inhibition, and induces free radical formation and oxidative stress. Therefore, a 6-OHDA-induced Parkinson's disease (PD) experimental model can be used to test a candidate molecule for use as an antioxidant that could be a promising therapeutic for treating Parkinson's disease. Recent studies have shown that vasoactive intestinal peptide (VIP) might be a good candidate agent for the treatment of PD. In this study, the anti-apoptotic and antioxidant actions of VIP were investigated using the 6-OHDA-lesioned rat model for PD. Twenty-four young adult Sprague-Dawley rats were used. The rats were separated into the following groups: group I (n = 8), sham operated; group II (n = 8), 6-OHDA lesioned; group III (n = 8), 6-OHDA lesioned + i.p. VIP-injected (25 ng/kg) every 2 days for 15 days. The first i.p. injection of VIP was made 1 h after the intrastriatal 6-OHDA microinjection. Antioxidant enzymatic activity [super oxide dismutase (SOD) and catalase (CAT)], lipid peroxidation, nitric oxide and DNA fragmentation were measured from homogenates isolated from the corpus striatum. SOD, CAT, malondialdehyde, and DNA fragmentation were measured using a spectrophotometer, and nitric oxide (NO) levels were measured by capillary electrophoresis. 6-OHDA significantly induced oxidative stress, lipid peroxidation, and DNA fragmentation in the corpus striatum of rats. VIP significantly protected neuronal tissue from oxidative stress and apoptosis by reducing lipid peroxidation and DNA fragmentation. 6-OHDA toxicity did not cause significant changes in NO production in the corpus striatum. However, VIP treatment significantly reduced NO levels in brain tissue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850490     DOI: 10.1007/s12031-011-9618-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  50 in total

1.  A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum.

Authors:  J P Kiss; E C Hennings; G Zsilla; E S Vizi
Journal:  Neurochem Int       Date:  1999-04       Impact factor: 3.921

2.  Modified method for the determination of capillary electrophoresis nitric oxide-correlated nitrate in tissue homogenates.

Authors:  M Tunçel; D Dogrukol-Ak; N Erkasap
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-02-25

3.  Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy.

Authors:  Neşe Tunçel; Erol Sener; Cem Cerit; Umut Karasu; Firdevs Gürer; Varol Sahintürk; Cengiz Bayçu; Dilek Ak; Zeynep Filiz
Journal:  Peptides       Date:  2005-05       Impact factor: 3.750

4.  Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide (VIP) on contractile force, oxygenation and antioxidant enzyme systems.

Authors:  N Tunçel; S Erden; K Uzuner; G Altiokka; M Tunçel
Journal:  Peptides       Date:  1997       Impact factor: 3.750

Review 5.  Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.

Authors:  P Jenner
Journal:  Acta Neurol Scand Suppl       Date:  1993

6.  Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase.

Authors:  H Berisha; H Foda; H Sakakibara; M Trotz; H Pakbaz; S I Said
Journal:  Am J Physiol       Date:  1990-08

7.  Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Authors:  D Offen; Y Sherki; E Melamed; M Fridkin; D E Brenneman; I Gozes
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

8.  Protection of rat retina from ischemia-reperfusion injury by vasoactive intestinal peptide (VIP): the effect of VIP on lipid peroxidation and antioxidant enzyme activity of retina and choroid.

Authors:  N Tunçel; H Başmak; K Uzuner; M Tunçel; G Altiokka; V Zaimoğlu; A Ozer; F Gürer
Journal:  Ann N Y Acad Sci       Date:  1996-12-26       Impact factor: 5.691

9.  Vasoactive intestinal peptide, a singlet oxygen quencher.

Authors:  B R Misra; H P Misra
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

10.  In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.

Authors:  Bobby Thomas; Karuppagounder S Saravanan; Kochupurackal P Mohanakumar
Journal:  Neurochem Int       Date:  2007-10-22       Impact factor: 3.921

View more
  16 in total

1.  PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglödi; Yousef Tizabi
Journal:  J Mol Neurosci       Date:  2013-04-28       Impact factor: 3.444

2.  Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.

Authors:  OrhanTansel Korkmaz; Hakan Ay; Emel Ulupinar; Neşe Tunçel
Journal:  J Mol Neurosci       Date:  2012-04-29       Impact factor: 3.444

3.  Alcoholic extract of Bacopa monniera Linn. protects against 6-hydroxydopamine-induced changes in behavioral and biochemical aspects: a pilot study.

Authors:  Chandrasekar Shobana; Radhakrishnan Ramesh Kumar; Thangarajan Sumathi
Journal:  Cell Mol Neurobiol       Date:  2012-04-17       Impact factor: 5.046

4.  Protective effects of poly (butyl) cyanoacrylate nanoparticles containing vasoactive intestinal peptide against 6-hydroxydopamine-induced neurotoxicity in vitro.

Authors:  Zhi-Ran Xu; Wu-Fang Wang; Xin-Fang Liang; Ze-Hua Liu; Yu Liu; Liang Lin; Xuan Zhu
Journal:  J Mol Neurosci       Date:  2014-10-19       Impact factor: 3.444

5.  VIP alleviates sepsis-induced cognitive dysfunction as the TLR-4/NF-κB signaling pathway is inhibited in the hippocampus of rats.

Authors:  Yujiao Yang; Debo Yun; Biqian Dong; Yuan Geng; Yong Wan
Journal:  J Mol Histol       Date:  2022-03-03       Impact factor: 2.611

6.  Antioxidant and Anti-Apoptotic Activity of Octadecaneuropeptide Against 6-OHDA Toxicity in Cultured Rat Astrocytes.

Authors:  Hadhemi Kaddour; Yosra Hamdi; Fatma Amri; Seyma Bahdoudi; Ibtissem Bouannee; Jérôme Leprince; Sami Zekri; Hubert Vaudry; Marie-Christine Tonon; David Vaudry; Mohamed Amri; Sana Mezghani; Olfa Masmoudi-Kouki
Journal:  J Mol Neurosci       Date:  2018-10-20       Impact factor: 3.444

7.  Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.

Authors:  İbrahim Halil Yelkenli; Emel Ulupinar; Orhan Tansel Korkmaz; Erol Şener; Gökhan Kuş; Zeynep Filiz; Neşe Tunçel
Journal:  J Mol Neurosci       Date:  2016-04-26       Impact factor: 3.444

8.  Effect of castration on pelvic neurons in the male pig.

Authors:  Jerzy Kaleczyc; Natalia Kasica-Jarosz; Zenon Pidsudko; Agnieszka Dudek; Magdalena Klimczuk; Waldemar Sienkiewicz
Journal:  Histochem Cell Biol       Date:  2020-01-01       Impact factor: 4.304

Review 9.  Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo.

Authors:  Stefano Morara; Anna Maria Colangelo; Luciano Provini
Journal:  Neural Plast       Date:  2015-07-26       Impact factor: 3.599

10.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.